Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab in locoregionally advanced nasopharyngeal carcinoma
NCT04907370Phase 3Active, not recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Aug 2021
- Primary completion
- Mar 2025
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of toripalimab in nasopharyngeal carcinoma (NPC), sponsored by Sun Yat-sen University. Started Aug 2021; status: active, not recruiting.
02
Drugs
toripalimab
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT04907370.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04907370.